Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioChemics Collaborates With Unilever
BioChemics has signed a research collaboration agreement with Unilever to utilize its proprietary topical delivery technology for the delivery of Unilever’s compounds. John Masiz, president and chief executive
BioChemics has signed a research collaboration agreement with Unilever to utilize its proprietary topical delivery technology for the delivery of Unilever’s compounds. John Masiz, president and chief executive
GlaxoSmithKline and XenoPort have reported top-line results from a phase II clinical trial evaluating GSK1838262/XP13512 (gabapentin enacarbil) in adult patients with neuropathic pain associated with post-herpetic neuralgia (PHN)
AstraZeneca and Bristol-Myers Squibb have reported that the European Commission has granted marketing authorisation for Onglyza (saxagliptin) across 27 countries of the EU. Onglyza is indicated as a
The New Hampshire facility makes plastic parts for use in research and medical labs, including pipettes, tubing, and plates. The company said this move will not affect its
GlaxoSmithKline (GSK) has received FDA’s Oncologic Drugs Advisory Committee (ODAC) recommendation in support of the approval of Votrient (pazopanib). Reportedly, the panel voted that the benefit-to-risk profile is
AstraZeneca has revealed the results of phase IIIb study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy. The study revealed that treatment with
SRI International has acquired a $6.3m contract by the National Institute of Mental Health (NIMH) to conduct preclinical safety studies of ligands that will be used for brain
ThromboGenics has revealed the results of phase IIa trial evaluating microplasmin intravitreal injection for the treatment of Diabetic Macular Edema. The company said that the trial was designed
Cytopia and YM BioSciences (YM) have entered into an agreement in which YM will acquire all the issued shares and options in Cytopia. Shareholders are expected to vote
Peregrine Pharmaceuticals has reported additional positive results from its phase II trial. The study evaluated bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung